Johnson & Johnson
1Q Revenues: $13 billion (+1.2%)
1Q Earnings: $3.3 billion* (+4.5%)
Comments: Worldwide Pharmaceutical sales were $5.6 billion for the quarter, down 2.2%. Sales results for Duragesic, Ultracet, and Sporanox, were all negatively impacted by generic competition. Risperdal, Remicade, Topamax, and Concerta sales were strong for the quarter.
* The first quarter included an after-tax gain of $368 million associated with the termination of the Guidant acquisition agreement, and after-tax in-process R&D charges of $29 million associated with the acquisitions of Hand Innovations LLC and Future Medical Systems S.A.
Magazine
